Hengrui Medicine Licenses Cancer Drug to Incyte in $795 Million Deal

Jiangsu Hengrui Medicine out-licensed global rights (ex-China) for its clinical-stage anti-PD-1 monoclonal antibody to Incyte in a deal potentially worth $795 million. Incyte paid $25 million upfront. Hengrui's SHR-1210 is expected to start a China Phase II trial in patients with solid tumor cancers in the next few months. Hengrui will retain rights in mainland China, Hong Kong, Macau and Taiwan. Incyte, headquartered in Delaware, described the relationship as a combination of licensing and collaboration. More details.... Stock Symbols: (SHA: 600276)  (NSDQ: INCY) Share this with colleagues: // //